Vincenzo Picardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6602351/publications.pdf

Version: 2024-02-01

566801 610482 46 652 15 24 citations h-index g-index papers 46 46 46 1121 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Advanced head and neck cancer in older adults: Results of a short course accelerated radiotherapy trial. Journal of Geriatric Oncology, 2021, 12, 441-445.	0.5	11
2	Challenges in lung and heart avoidance for postmastectomy breast cancer radiotherapy: Is automated planning the answer?. Medical Dosimetry, 2021, 46, 295-303.	0.4	9
3	Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey. Anticancer Research, 2021, 41, 1985-1995.	0.5	7
4	Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2). Frontiers in Oncology, 2020, 10, 626400.	1.3	3
5	PO-0809 Gross Tumor Volume delineation in pancreatic cancer using MRI: final results of a multicenter study Radiotherapy and Oncology, 2019, 133, S421-S422.	0.3	O
6	Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers. Acta Oncológica, 2019, 58, 439-447.	0.8	13
7	Efficacy and safety of 3D-conformal half body irradiation in patients with multiple bone metastases. Clinical and Experimental Metastasis, 2018, 35, 747-752.	1.7	5
8	Partially ablative radiotherapy (<scp>PAR</scp>) for large mass tumors using simultaneous integrated boost: A doseâ€escalation feasibility study. Journal of Applied Clinical Medical Physics, 2018, 19, 35-43.	0.8	7
9	PO-0716: High dose chemoradiation in glioblastoma patients: feasibility and safety of a phase I trial. Radiotherapy and Oncology, 2018, 127, S366-S367.	0.3	O
10	EP-1430: Biliary cancer definitive radiotherapy: an atlas for ctv definition with elective nodal irradiation. Radiotherapy and Oncology, 2018, 127, S777-S778.	0.3	0
11	EP-1463: Phase II study of adaptive high-dose neoadjuvant radiotherapy in high risk rectal cancer. Radiotherapy and Oncology, 2018, 127, S794-S795.	0.3	O
12	EP-2200: Statistical process control for VMAT quality assurance: an eight-year retrospective study. Radiotherapy and Oncology, 2018, 127, S1215-S1216.	0.3	O
13	Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients. Clinical and Translational Radiation Oncology, 2017, 4, 8-14.	0.9	47
14	Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study. Clinical Colorectal Cancer, 2017, 16, 16-22.	1.0	17
15	Palliative Short-Course Radiation Therapy inÂRectal Cancer: A Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1184-1190.	0.4	36
16	Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study. Future Oncology, 2016, 12, 779-787.	1.1	7
17	EP-1424: Palliative short-course radiotherapy in rectal cancer: a phase II study. Radiotherapy and Oncology, 2016, 119, S662-S663.	0.3	0
18	EP-1556: VMAT in nasopharyngeal tumor: clinical implications after a change in the dose calculation algorithm. Radiotherapy and Oncology, 2016, 119, S721-S722.	0.3	1

#	Article	IF	CITATIONS
19	Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study. Anticancer Research, 2016, 36, 4081-7.	0.5	7
20	Radiological and clinical results following high-dose intensity-modulated radiotherapy in recurrent craniopharyngioma: A case report. Oncology Letters, 2015, 10, 2491-2494.	0.8	0
21	Adjuvant Chemoradiotherapy in Gastric Cancer: A Pooled Analysis of the AIRO Gastrointestinal Group Experience. Tumori, 2015, 101, 91-97.	0.6	2
22	Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer. Radiologia Medica, 2014, 119, 343-7.	4.7	3
23	Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. Medical Dosimetry, 2014, 39, 108-116.	0.4	23
24	FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase l–II study. Journal of Chemotherapy, 2014, 26, 353-358.	0.7	7
25	Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. British Journal of Radiology, 2013, 86, 20130274.	1.0	7
26	Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial. Oncology Letters, 2013, 5, 1889-1896.	0.8	14
27	Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Research, 2013, 33, 2785-9.	0.5	21
28	Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study. Anticancer Research, 2013, 33, 4585-9.	0.5	4
29	Quality of Life and Toxicity of Stereotactic Radiotherapy in Pancreatic Tumors: A Case Series. Cancer Investigation, 2012, 30, 149-155.	0.6	23
30	Neoadjuvant Accelerated Concomitant Boost Radiotherapy and Multidrug Chemotherapy in Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 424-431.	0.6	16
31	Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiation Oncology, 2012, 7, 86.	1.2	29
32	Daily On-Line Set-Up Correction in 3D-Conformal Radiotherapy: Is It Feasible?. Tumori, 2012, 98, 441-444.	0.6	26
33	Volumetric Modulated Arc Therapy with Simultaneous Integrated Boost for Locally Advanced Rectal Cancer. Clinical Oncology, 2012, 24, 261-268.	0.6	31
34	Daily on-line set-up correction in 3D-conformal radiotherapy: is it feasible?. Tumori, 2012, 98, 441-4.	0.6	11
35	Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: Results of a phase II study. Acta Oncol³gica, 2011, 50, 1151-1157.	0.8	28
36	Feasibility Study of Moderately Accelerated Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin After Induction Chemotherapy in Locally Advanced Head-and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1073-1080.	0.4	12

3

#	Article	IF	CITATIONS
37	A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 194-205.	0.7	136
38	3D-Conformal Versus Intensity-Modulated Postoperative Radiotherapy of Vaginal Vault: A Dosimetric Comparison. Medical Dosimetry, 2010, 35, 135-142.	0.4	15
39	Postoperative Intensity-Modulated Radiotherapy in Low-Risk Endometrial Cancers: Final Results of a Phase I Study. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1390-1395.	0.4	10
40	Eccrine syringofibroadenoma radiation treatment of an unusual presentation. Dermatologic Therapy, 2010, 23, S20-S23.	0.8	8
41	Active Breathing Coordinator in Adjuvant Three-Dimensional Conformal Radiotherapy of Early Stage Breast Cancer: A Feasibility Study. Tumori, 2010, 96, 417-423.	0.6	4
42	Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. Acta Oncol \tilde{A}^3 gica, 2010, 49, 418-422.	0.8	6
43	Late Tonsil Metastases from Renal Cell Cancer: A Case Report. Tumori, 2009, 95, 521-524.	0.6	19
44	Videoconferencing to Enhance the Integration between Clinical Medicine and Teaching: A Feasibility Study. Tumori, 2008, 94, 822-829.	0.6	7
45	Impact of dose and volume on subcutaneous fibrosis. Rays, 2005, 30, 169-73.	0.2	1
46	Hodgkin's disease inHIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor. Annals of Oncology, 2002, 13, 1157-1159.	0.6	19